Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The Breast - Volume 24, Issue 3, June 2015, Pages 182-190

Véronique Diéras, Hans Wildiers, Jacek Jassem, Luc Y. Dirix, Jean-Paul Guastalla, Petri Bono, Sara A. Hurvitz, Anthony Gonçalves, Gilles Romieu, Steven A. Limentani, Guy Jerusalem, K.C. Lakshmaiah, Henri Roché, Pedro Sánchez-Rovira,